Bellerophon submits investigational new drug application to study inhaled nitric oxide therapy for covid-19

Bellerophon therapeutics submits investigational new drug application to study inopulse® inhaled nitric oxide therapy for the treatment of covid-19.bellerophon - study, called pulse-cvd19-001, will evaluate efficacy and safety of inopulse in patients with covid-19 who require supplemental oxygen..bellerophon - pulse-cvd19-001 protocol aims to enroll up to 500 patients with covid-19 who will be treated with inopulse or standard of care.bellerophon therapeutics inc - in parallel, co has applied for federal funding, through barda and nih to support proposed ind study..
BLPH Ratings Summary
BLPH Quant Ranking